Matches in Ubergraph for { <https://frink.apps.renci.org/.well-known/genid/Ba551d48f0265f1db1f06ca255d5d162c> ?p ?o ?g. }
Showing items 1 to 5 of
5
with 100 items per page.
- Ba551d48f0265f1db1f06ca255d5d162c NCIT_P378 "NCI" @default.
- Ba551d48f0265f1db1f06ca255d5d162c type Axiom @default.
- Ba551d48f0265f1db1f06ca255d5d162c annotatedProperty IAO_0000115 @default.
- Ba551d48f0265f1db1f06ca255d5d162c annotatedSource NCIT_C78204 @default.
- Ba551d48f0265f1db1f06ca255d5d162c annotatedTarget "The anhydrous form of regorafenib, an orally bioavailable small molecule with potential antiangiogenic and antineoplastic activities. Regorafenib binds to and inhibits vascular endothelial growth factor receptors (VEGFRs) 2 and 3, and Ret, Kit, PDGFR and Raf kinases, which may result in the inhibition of tumor angiogenesis and tumor cell proliferation. VEGFRs are receptor tyrosine kinases that play important roles in tumor angiogenesis; the receptor tyrosine kinases RET, KIT, and PDGFR, and the serine/threonine-specific Raf kinase are involved in tumor cell signaling." @default.